Commercial applications for soy isoflavones have grown significantly in recent years. Isoflavones are used in health foods and as nutritional supplements. More recently they are being investigated as antioxidants, protecting skin from UV damage when taken orally or used topically. More importantly, isoflavones and their derivatives have potential to be used as pharmaceuticals in the fight against certain cancers, heart disease, and osteoporosis. Fermalogic identified a method for the isolation of isoflavones as a by-product of the Saccharopolyspora erythraea erythromycin fermentation, but in order to be commercially successful, a problem with degradation of the isoflavones during the fermentation had to be solved. In Phase I of this project the first metabolite of the isoflavone degradation pathway was identified. During Phase II we hope to find the gene responsible for this degradation and inactivate it. This should raise production levels of isoflavones to commercially useful levels. In addition/other bacterial fermentations will be investigated for the production of new biologically active isoflavone metabolites.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA093165-02
Application #
6694229
Study Section
Special Emphasis Panel (ZRG1-SSS-T (10))
Program Officer
Ross, Sharon A
Project Start
2001-09-01
Project End
2005-08-31
Budget Start
2003-09-30
Budget End
2004-08-31
Support Year
2
Fiscal Year
2003
Total Cost
$575,403
Indirect Cost
Name
Fermalogic, Inc.
Department
Type
DUNS #
798525234
City
Chicago
State
IL
Country
United States
Zip Code
60610
Weber, J Mark; Reeves, Andrew R; Seshadri, Ramya et al. (2013) Biotransformation and recovery of the isoflavones genistein and daidzein from industrial antibiotic fermentations. Appl Microbiol Biotechnol 97:6427-37